Taxpayers and charities helped develop Zolgensma. Then it debuted at a record price, ushering in a new class of wildly expensive drugs. Its story upends the widely held conception that high prices reflect huge industry investments in innovation.
You must log in or register to comment.
PharmaBros and PharmaBoomers, who would have though they’ll be birds of a feather.
